KBC Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$373M Sell
2,679,656
-564,970
-17% -$79.1M 0.94% 13
2025
Q4
$398M Buy
3,244,626
+283,659
+10% +$34.5M 0.91% 18
2025
Q3
$329M Buy
2,960,967
+619,174
+26% +$70.4M 0.79% 18
2025
Q2
$260M Buy
2,341,793
+496,708
+27% +$52.9M 0.7% 20
2025
Q1
$207M Sell
1,845,085
-216,483
-11% -$22.3M 0.64% 25
2024
Q4
$190M Sell
2,061,568
-220,951
-10% -$19.9M 0.52% 27
2024
Q3
$191M Sell
2,282,519
-1,344,697
-37% -$103M 0.58% 26
2024
Q2
$249M Buy
3,627,216
+468,039
+15% +$31.2M 0.75% 20
2024
Q1
$231M Buy
3,159,177
+1,737,617
+122% +$134M 0.74% 25
2023
Q4
$115M Buy
1,421,560
+184,805
+15% +$14.4M 0.41% 54
2023
Q3
$92.7M Sell
1,236,755
-210,700
-15% -$16.2M 0.38% 57
2023
Q2
$112M Buy
1,447,455
+515,435
+55% +$41.1M 0.46% 50
2023
Q1
$77.3M Buy
932,020
+79,280
+9% +$6.57M 0.33% 68
2022
Q4
$73.2M Buy
852,740
+56,923
+7% +$4.51M 0.36% 62
2022
Q3
$49.1M Buy
795,817
+27,919
+4% +$1.76M 0.26% 93
2022
Q2
$47.5M Buy
767,898
+77,533
+11% +$4.8M 0.24% 104
2022
Q1
$41M Sell
690,365
-214,959
-24% -$13.7M 0.16% 153
2021
Q4
$65.7M Buy
905,324
+76,445
+9% +$5.27M 0.22% 115
2021
Q3
$57.9M Sell
828,879
-426,903
-34% -$30M 0.21% 121
2021
Q2
$86.5M Buy
1,255,782
+228,782
+22% +$15.3M 0.16% 153
2021
Q1
$66.4M Buy
1,027,000
+78,186
+8% +$5.04M 0.13% 187
2020
Q4
$294M Sell
948,814
-168,046
-15% -$10.1M 0.13% 193
2020
Q3
$70.6M Buy
1,116,860
+56,378
+5% +$3.91M 0.21% 113
2020
Q2
$81.6M Buy
1,060,482
+452,576
+74% +$34.7M 0.27% 80
2020
Q1
$45.4M Sell
607,906
-80,746
-12% -$5.58M 0.38% 57
2019
Q4
$44.7M Sell
688,652
-130,094
-16% -$8.47M 0.28% 80
2019
Q3
$51.9M Buy
818,746
+400,483
+96% +$26.2M 0.38% 51
2019
Q2
$28.3M Buy
418,263
+55,323
+15% +$3.64M 0.22% 113
2019
Q1
$23.6M Sell
362,940
-19,393
-5% -$1.29M 0.19% 127
2018
Q4
$23.9M Sell
382,333
-53,410
-12% -$3.73M 0.27% 87
2018
Q3
$33.6M Buy
435,743
+222,952
+105% +$16.8M 0.25% 101
2018
Q2
$15.1M Sell
212,791
-17,951
-8% -$1.27M 0.13% 211
2018
Q1
$17.4M Sell
230,742
-27,406
-11% -$2.18M 0.16% 166
2017
Q4
$18.5M Sell
258,148
-486,685
-65% -$37M 0.16% 167
2017
Q3
$60.3M Buy
744,833
+84,946
+13% +$6.5M 0.55% 35
2017
Q2
$46.7M Sell
659,887
-632,994
-49% -$42.1M 0.45% 45
2017
Q1
$87.8M Buy
1,292,881
+162,841
+14% +$11.5M 0.79% 15
2016
Q4
$80.9M Buy
1,130,040
+128,513
+13% +$9.55M 0.8% 13
2016
Q3
$79.2M Buy
1,001,527
+304,754
+44% +$24.8M 0.94% 12
2016
Q2
$58.1M Buy
696,773
+217,111
+45% +$19.3M 0.83% 15
2016
Q1
$44.1M Sell
479,662
-33,667
-7% -$3.04M 0.73% 19
2015
Q4
$51.9M Buy
513,329
+21,151
+4% +$2.2M 0.96% 10
2015
Q3
$48.3M Sell
492,178
-10,936
-2% -$1.21M 0.97% 10
2015
Q2
$58.9M Buy
503,114
+211,641
+73% +$23.1M 0.76% 14
2015
Q1
$28.6M Sell
291,473
-281,898
-49% -$28.6M 0.37% 70
2014
Q4
$54M Buy
573,371
+369,189
+181% +$38.2M 0.64% 23
2014
Q3
$21.7M Sell
204,182
-794,879
-80% -$77.8M 0.76% 11
2014
Q2
$82.8M Sell
999,061
-70,244
-7% -$5.47M 0.95% 14
2014
Q1
$75.8M Sell
1,069,305
-48,466
-4% -$3.8M 1.2% 8
2013
Q4
$83.9M Buy
1,117,771
+47,956
+4% +$3.34M 1.27% 9
2013
Q3
$67.3M Buy
1,069,815
+230,253
+27% +$13.8M 1.08% 9
2013
Q2
$43M Buy
+839,562
New +$43.8M 0.8% 16

Other funds holding GILD

KBC Group's GILD Position: Q1 2026 in Review

KBC Group reduced its Gilead Sciences (GILD) stake by 17% in Q1 2026, selling an estimated $79.1M and leaving 2,679,656 shares worth $373M. The position accounts for 0.94% of the portfolio, ranked #13.

KBC Group first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $398M in Q4 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • KBC Group held 2,679,656 shares of Gilead Sciences worth $373M as of Q1 2026.
  • KBC Group sold 564,970 Gilead Sciences shares in Q1 2026, an estimated $79.1M.
  • Gilead Sciences made up 0.94% of KBC Group's portfolio in Q1 2026, its #13 holding.
  • KBC Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • KBC Group's Gilead Sciences position peaked at $398M in Q4 2025.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.